HomeAI · summaries
Storia in 5 fonti
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) was approved as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and…
- ·
medpagetoday.com
FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility
